RSS

Entresto

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Healthcare solutions provider, Novartis, has announced new data demonstrating that its twice-a-day medicine, Entresto (sacubitril/valsartan) can be initiated early and safely in hospitalised patients after an acute heart failure episode. Read more

News

Novartis Pharmaceuticals, in cooperation with the US Consumer Product Safety Commission (CPSC) and the Food and Drug Administration (FDA), has voluntarily implemented a corrective action plan concerning Zofran and Entresto packages in the US. Read more

News

Novartis has established FortiHFy, a global clinical programme, to generate additional data on the effects of the company’s novel heart failure medicine, Entrestro Read more

News

The heart failure market is set to rise by £5.8bn ($8.6bn) within the next century, according to GlobalData Read more

News

Novartis’ Entresto has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of heart failure Read more

News

The European Commission (EC) has approved Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) Read more

News